Objective: Many Black breast cancer patients experience chemotherapy-induced peripheral neuropathy (CIPN). Our study assessed Black breast cancer patients' questions about a biomarker test that can predict likelihood of CIPN.
Methods: Nineteen Black women who were previous/current breast cancer patients participated in focus groups.